Close Menu

Breaking News

Other big gainers last month included Accelerate Diagnostics and Natera, and share prices of 23 of the 27 companies in the index increased month over month.

Seventh Sense Biosystems markets a one-step, push-button device called Tap that uses a microneedle array to collect capillary blood from the arm.

The firm's CEO said it is continuing to develop its distributor network to make its tests available in centralized and decentralized settings globally.

In issuing a proposed limited local coverage determination for Opko Health's 4Kscore, Novitas changed course from a previously issued non-coverage determination.

The test measures levels of seven auto-antibodies to tumor-associated antigens, and is designed to detect all forms of lung cancer at any stage.

iCubate said that it now has a comprehensive solution within European markets for the detection of bloodstream bacteria and important resistance markers.

The test uses turbidimetry to measure levels of fecal calprotectin, a neutrophilic protein biomarker of intestinal mucosal inflammation.

The new partnership also gives clinical Dx analytics firm Prognos access to Datavant's pharma and biotech customers.

The agreement consists of a $100 million revolving credit facility, a $100 million initial term loan, and a $50 million delayed-draw term loan.

Regulators in the country granted additional approval of the test as a companion diagnostic for Rozlytrek, marketed in Japan by Roche's Chugai Pharmaceutical.

The Almeda, California immunodiagnostics developer had been developing immunoassay technologies for 16 years, with ties to many giants in the industry.

The closure has no impact on the firm's other Los Gatos location, the original home of GeneWeave Biosciences, which Roche acquired in 2015 for up to $425 million.

Under the partnership, Heidelberg-based Eluthia will become the primary distributor of BGI's NIFTY noninvasive prenatal test in Germany.

The study said that a revision of USPSTF's guidelines would lead to more equitable lung cancer screening for African American smokers at high risk for the disease.

Sonic Healthcare sold its 85 percent stake in GLP. Abbott has acquired the remaining 15 percent interest in the German firm and will collaborate with Sonic in the long term.

The firm said that its multiplex point-of-care test uses 10 microliters of blood from a fingertip and provides quantitative results in about 15 minutes.

The firm, which markets a clinical immunosequencing assay for leukemia and multiple myeloma, had originally expected to sell its shares at $15 to $17 apiece.

Quanterix said that the acquisition will secure the supply of neurofilament light antibodies that are critical to its Simoa assays and services.

Guardant told a federal judge that it believes Foundation Medicine and Personal Genome Diagnostics are coordinating to invalidate its patents.

The VioOne HIV supplemental assay is for confirming and differentiating individual antibodies directed to various gene products of HIV-1 and HIV-2.

The firm said it needs more time to ensure that the DetermaVu assay is providing the most consistent and sensitive results for patients.

AnchorDx, based in Guangzhou in southern China, will use Illumina's MiSeqDx sequencer to develop IVD cancer test kits and data analysis software.

The firm expect to raise gross proceeds of $15 million, or $17.25 million if the offering's underwriter exercises its option to purchase additional shares.

The tests run on the firm's sample-to-result automated molecular diagnostics instruments designed for use by high-volume labs.

Pages